Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $100.00 by Analysts at Cantor Fitzgerald

Vera Therapeutics (NASDAQ:VERA) had its price objective trimmed by Cantor Fitzgerald from $107.00 to $100.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Vera Therapeutics’ FY2025 earnings at ($2.74) EPS.

A number of other equities analysts also recently issued reports on VERA. Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. Guggenheim increased their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price on the stock. Finally, HC Wainwright began coverage on Vera Therapeutics in a research report on Monday, May 5th. They issued a “buy” rating and a $75.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $63.80.

Vera Therapeutics Stock Down 1.2 %

VERA stock opened at $21.77 on Wednesday. The stock has a market capitalization of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The business has a fifty day moving average price of $24.22 and a 200-day moving average price of $34.72.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the firm earned ($0.56) EPS. Equities analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VERA. Barclays PLC lifted its position in shares of Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after buying an additional 41,394 shares in the last quarter. SG Americas Securities LLC raised its stake in Vera Therapeutics by 116.7% during the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock valued at $857,000 after purchasing an additional 10,916 shares in the last quarter. KBC Group NV lifted its position in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after purchasing an additional 1,387 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Vera Therapeutics by 27.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after buying an additional 2,882 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after acquiring an additional 366,763 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.